Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. The company offers its enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids and forms the basis of ENHANZE drug delivery technology platform that enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. In addition, the company markets Hylenex recombinant (hyaluronidase human injection), which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.